DPM Stock Overview
Engages in the manufacture and sale of pharmaceuticals, food ingredients and additives, veterinary medicines, and others in Japan, North America, China, and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 5/6 |
| Future Growth | 3/6 |
| Past Performance | 0/6 |
| Financial Health | 2/6 |
| Dividends | 0/6 |
Sumitomo Pharma Co., Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | JP¥3.74 |
| 52 Week High | JP¥4.22 |
| 52 Week Low | JP¥1.64 |
| Beta | 0.63 |
| 11 Month Change | 6.25% |
| 3 Month Change | -8.33% |
| 1 Year Change | 27.21% |
| 33 Year Change | -65.05% |
| 5 Year Change | -78.51% |
| Change since IPO | -60.63% |
Recent News & Updates
Recent updates
Shareholder Returns
| DPM | DE Pharmaceuticals | DE Market | |
|---|---|---|---|
| 7D | 6.9% | 1.4% | 0.8% |
| 1Y | 27.2% | -18.4% | 9.1% |
Return vs Industry: DPM exceeded the German Pharmaceuticals industry which returned -19.3% over the past year.
Return vs Market: DPM exceeded the German Market which returned 8.5% over the past year.
Price Volatility
| DPM volatility | |
|---|---|
| DPM Average Weekly Movement | 8.6% |
| Pharmaceuticals Industry Average Movement | 6.9% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.8% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: DPM's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: DPM's weekly volatility (9%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1897 | 4,980 | Toru Kimura | www.sumitomo-pharma.com |
Sumitomo Pharma Co., Ltd. engages in the manufacture and sale of pharmaceuticals, food ingredients and additives, veterinary medicines, and others in Japan, North America, China, and internationally. The company offers pharmaceutical products, such as therapeutic agents for Parkinson’s disease, uterine fibroids, depression, type 2 diabetes, systemic fungal infection, hypertension, pruritus, advanced prostate cancer, overactive bladder, chronic obstructive pulmonary disease, angina pectoris, and arrhythmia. It provides products for atypical antipsychotic, cultured thymus tissue for pediatric congenital athymia, antiepileptic, and carbapenem antibiotic; and Fabry disease drugs.
Sumitomo Pharma Co., Ltd. Fundamentals Summary
| DPM fundamental statistics | |
|---|---|
| Market cap | €1.51b |
| Earnings (TTM) | -€1.73b |
| Revenue (TTM) | €2.12b |
0.7x
P/S Ratio-0.9x
P/E RatioIs DPM overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| DPM income statement (TTM) | |
|---|---|
| Revenue | JP¥342.67b |
| Cost of Revenue | JP¥138.58b |
| Gross Profit | JP¥204.08b |
| Other Expenses | JP¥483.54b |
| Earnings | -JP¥279.46b |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
Jan 31, 2025
| Earnings per share (EPS) | -703.41 |
| Gross Margin | 59.56% |
| Net Profit Margin | -81.55% |
| Debt/Equity Ratio | 340.8% |
How did DPM perform over the long term?
See historical performance and comparison